Please assess the completion status of the following clinical trial:

Trial Title: Study of Ivacaftor in Subjects With Cystic Fibrosis (CF) Who Have a Non-G551D CF Transmembrane Conductance Regulator (CFTR) Gating Mutation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female with confirmed diagnosis of CF~* At least 1 allele of the following CFTR gating mutations: G178R, S549N, S549R, G551S, G970R, G1244E, S1251N, S1255P, G1349D~* Percent predicted forced expiratory volume in 1 second (FEV1) greater than or equal to (\>=) 40 percent (%) predicted normal for age, sex, and height~* 6 years of age or older~* Minimum weight of 15 kilogram (kg) at screening~* Females of childbearing potential must not be pregnant~* Willing to comply with contraception requirements~Exclusion Criteria:~* G551D-CFTR mutation on at least 1 allele~* History of any illness or condition that might confound the results of the study or pose an additional risk in administering ivacaftor to the subject~* An acute upper or lower respiratory infection, pulmonary exacerbation, or changes in therapy (including antibiotics) for pulmonary disease within 4 weeks before the first dose of study drug~* History of solid organ or hematological transplantation~* History of alcohol, medication or illicit drug abuse within 1 year before the first dose of study drug~* Ongoing participation in another therapeutic clinical study or prior participation in an investigational drug study within 30 days before screening~* Use of inhaled hypertonic saline treatment~* Use of any inhibitors or inducers of cytochrome (CYP) P450 3A~* Evidence of cataract or lens opacity at screening

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Part 1: Ivacaftor First, Then Placebo (Type: EXPERIMENTAL): Ivacaftor 150 milligram (mg) tablet orally twice daily for 8 weeks in treatment period 1 followed by placebo matched to ivacaftor tablet orally twice daily for 8 weeks in treatment period 2. Washout out period of 4 to 8 weeks was maintained between each treatment period.
- Part 1: Placebo First, Then Ivacaftor (Type: EXPERIMENTAL): Placebo matched to ivacaftor tablet orally twice daily for 8 weeks in treatment period 1 followed by ivacaftor 150 mg tablet orally twice daily for 8 weeks in treatment period 2. Washout out period of 4 to 8 weeks was maintained between each treatment period.
- Part 2: Ivacaftor (Type: EXPERIMENTAL): Ivacaftor 150 mg tablet orally twice daily for 16 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).